sonrotoclax (BGB-11417) / BeOne Medicines - LARVOL DELTA

Diagnosis and Management of Waldenstrom's Macroglobulinemia (ICML 2025) - P2 | "New or emerging options for patients progressing on c-BTKi include pirtobrutinib, BGB-16673, venetoclax, and sonrotoclax...CXCR4 antagonists such as plerixafor or ulocuplumab can sensitize CXCR4Mut-expressing WM cells to ibrutinib [22-24]...6 BTK Mutations BTKCys481 is the binding site for covalent BTK inhibitors (cBTK-i), including ibrutinib, zanubrutinib, acalabrutinib, orelabrutinib and tirabrutinib...For symptomatic treatment-naïve patients, chemoimmunotherapy with bendamustine and rituximab (Benda-R), dexamethasone, rituximab, and cyclophosphamide (DRC), as well as cBTK-i can be considered...Additional options in second or later relapse include re-use of chemotherapy if a response lasted for > 3 years, alternative chemoimmunotherapy, nucleoside analogs, or everolimus [38]...Zanubrutinib in combination with ixazomib and dexamethasone (ZID) is being investigated in a study in China (NCT04463953) and has shown high levels of response activity and good..."

IO biomarker • Hematological Malignancies • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia • BCLAF1 • CXCL12 • FOXO3 • IL10 • IL6 • IRAK4 • MYD88 • PLCG2 • SYK • TNFAIP3 • TRAF3IP2

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation (ICML 2025) - P=N/A, P2, P3 | "BRUIN CLL-321 is a phase 3, registrational study that evaluated pirtobrutinib compared to the investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) [23]...Nemtabrutinib is now being evaluated in the registrational, phase 3 BELLWAVE-010 trial (NCT05947851) for patients with R/R CLL, comparing nemtabrutinib plus venetoclax to venetoclax plus rituximab...An ongoing, open-label, first-in-human phase 1/2 study is evaluating the BTK degrader BGB-16673 as monotherapy in patients with R/R CLL [27, 28]...NX-2127 is an investigational, first-in-class BTK degrader currently being evaluated in a phase 1 trial for patients with relapsed or refractory B-cell malignancies, CLL [29, 30]...NX-5948 is another investigational and more selective BTK degrader in an ongoing Phase 1a/1b clinical trial...This trial aims to establish lisaftoclax plus acalabrutinib as a potential alternative to venetoclax-based BTKi combination..."

IO biomarker • Acute Myelogenous Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • BCL2L1 • TP53

THE BTK DEGRADER BGB-16673 AND THE BCL2 INHIBITOR SONROTOCLAX SHOWS ANTI-TUMOR ACTIVITY AS SINGLE AGENTS AND IN COMBINATION IN MARGINAL ZONE LYMPHOMA MODELS (ICML 2025) - "The activity did not differ from the BTK inhibitor zanubrutinib and, accordingly, was limited in cells resistant to ibrutinib (n. = 2), idelalisib (n...= 1), and copanlisib/venetoclax (n...Karpas1718, SSK41, VL51 and HC1 were exposed to BGB-16673 plus lenalidomide, selinexor, venetoclax, sonrotoclax (BGB-11417), bendamustine, tazemetostat and rituximab... Its ability to degrade BTK protein, combined with its synergistic effects with other targeted therapies, positions BGB-16673 as a promising candidate for further development in MZL patients. The 2nd generation BCL2 inhibitor sonrotoclax appears as another drug to be explored in the same patient populations, possibly combining the two molecules."

B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology • BCL2L1 • CRBN • MCL1

BGB-11417-203: A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia (clinicaltrials.gov) - P2 | N=105 | Recruiting | Sponsor: BeiGene | Trial primary completion date: Nov 2027 ➔ Dec 2026

Monotherapy • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia • BCL2

INTERNATIONAL OVERVIEW OF CHINESE NOVEL DRUGS IN INDOLENT LYMPHOMA (ICML 2025) - "China's groundbreaking advancements have been achieved in indolent lymphoma therapies, anchored by Zanubrutinib, a best-in-class BTK inhibitor. Key clinical trials (ALPINE, ROSEWOOD) demonstrate its superior progression-free survival in CLL/SLL and FL, supported by global expansion into over 70 markets. Beyond BTK inhibition, other novel drugs include BTK degrader (BGB-16673), BCL-2 inhibitor (Sonrotoclax), and CAR-T (Axi-cel and Rel-cel), positioning China at the forefront of indolent lymphoma research."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Oncology

COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) + ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (ICML 2025) - P1, P3 | "Introduction: Sonrotoclax (sonro; BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax. Sonro + zanu combination tx was well tolerated and demonstrated encouraging antitumor activity, with a CR rate of 62.2%, and responses in pts with prior BTKi tx. A registrational phase 3 study (NCT06742996) further assessing this combination with sonro 320 mg is recruiting."

Clinical • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Myelodysplastic Syndrome • Oncology

MECHANISMS OF RESISTANCE TO SMALL MOLECULE INHIBITORS (ICML 2025) - "The relevant approved agents are: Ibrutinib, acalbrutinib and Zanubrutinib as covalent inhibitors, and Pirtobrutinib as a non-covalent inhibitor of BTK, Idelalisib as a PI3K inhibitor and Venetoclax as a BCL2 inhibitor. Although these pathway specific resistance mechanisms do not predict for intrinsic resistance to the other drug class (BTK vs. BCL2 inhibitors), early single-cell data suggest that "double class" resistant disease can involve both compound mutant clones (harboring both BTK and BCL2) mutations, or heterogeneous multi-clonal mechanisms. The mechanisms of acquired resistance to currently approved agents have significant implications both for clinical management and treatment sequencing decisions and the potential utility of novel agents targeting these same pathways (such as BTK-degraders BGB-16673 and NX-5984 and the BCL2 inhibitor sonrotoclax)."

IO biomarker • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Richter's Syndrome • Waldenstrom Macroglobulinemia • BCL2L1 • MCL1

BGB-11417-302, A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF SONROTOCLAX (BGB-11417) + ZANUBRUTINIB VERSUS PLACEBO + ZANUBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (ICML 2025) - P1, P3 | "Inhibition of B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) with venetoclax + ibrutinib, respectively, has demonstrated efficacy in patients with relapsed or refractory MCL; however, use of this regimen can be limited by toxicity and development of treatment resistance. Secondary endpoints include overall survival, PFS (assessed by investigator), overall response rate, complete response rate, duration of response, and safety/tolerability. Recruitment is ongoing."

Clinical • P3 data • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS WITH T(11; 14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM): AN ALL-ORAL TREATMENT (ICML 2025) - P1/2 | "Sonrotoclax (sonro; BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no drug accumulation. This ongoing study showed that the all-oral combination of sonro + dex is tolerable, with low rates of infection and hematologic toxicity, and promising efficacy, with an ORR of 81% in the 640-mg cohort, in this t(11; 14)-positive R/R MM population. Additional tx combinations with sonro are being investigated."

Clinical • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology

SONROTOCLAX (BGB-11417), A NOVEL BCL2 INHIBITOR, PLUS ZANUBRUTINIB (ZANU) DEMONSTRATES DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY CLL/SLL: UPDATED PHASE 1 RESULTS (ICML 2025) - P1 | "Introduction: Sonrotoclax (sonro; BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax. Zanu, a next-generation BTK inhibitor (BTKi), is highly effective in CLL with superior PFS and fewer cardiac AEs versus ibrutinib in pts with R/R CLL/SLL... Sonro + zanu combination tx demonstrated a tolerable safety profile across all dose levels tested. Antitumor activity of this combination is encouraging, with a 95.7% ORR, deep responses, and uMRD observed in pts with R/R CLL/SLL, including those with previous BTKi tx."

IO biomarker • P1 data • Chronic Lymphocytic Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Small Lymphocytic Lymphoma • IGH

CLL-RT1 EXTENSION TRIAL: ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD1 INHIBITOR, PLUS SONROTOCLAX, A BCL2 INHIBITOR, FOR TREATMENT OF RICHTER TRANSFORMATION (ICML 2025) - "Potential patients can be discussed any time at CLL-Studie@uk-koeln.de and +4922147888220. Keyword: ongoing trials"

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome

BGB-11417-105: A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=246 | Recruiting | Sponsor: BeiGene | N=167 ➔ 246

Enrollment change • Monotherapy • Hematological Malignancies • Multiple Myeloma • Oncology

BGB-11417-302, A PHASE?3, RANDOMIZED, DOUBLE-BLIND STUDY OF SONROTOCLAX (BGB-11417) + ZANUBRUTINIB VS PLACEBO + ZANUBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (EHA 2025) - P1, P3 | "Inhibition of B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) with venetoclax + ibrutinib, respectively, has demonstrated efficacy in patients with relapsed or refractory MCL; however, use of this regimen can be limited by toxicity and development of treatment resistance. Secondary endpoints include overall survival, PFS (assessed by investigator), overall response rate, complete response rate, duration of response, and safety/tolerability. Recruitment is ongoing."

Clinical • P3 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Lymphoma • Mantle Cell Lymphoma • Oncology

UPDATED RESULTS FROM THE PHASE 1 STUDY OF SONROTOCLAX (BGB-11417), A NOVEL BCL2 INHIBITOR, IN COMBINATION WITH ZANUBRUTINIB FOR RELAPSED/REFRACTORY CLL/SLL DEMONSTRATE DEEP AND DURABLE RESPONSES (EHA 2025) - P1 | "Sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no drug accumulation. Zanubrutinib (zanu), a next-generation BTK inhibitor, is highly effective in CLL, including in pts with high-risk disease features, and has shown superior progression-free survival (PFS) with fewer cardiac AEs vs ibrutinib in a randomized study in pts with R/R CLL/SLL... Sonrotoclax + zanu combination tx demonstrated a tolerable safety profile across all dose levels tested. Antitumor activity of this combination is encouraging, with a 95.7% ORR, deep responses, and uMRD observed in pts with R/R CLL/SLL, including those previously treated with a BTK inhibitor."

Combination therapy • IO biomarker • P1 data • Cerebral Hemorrhage • Chronic Lymphocytic Leukemia • CNS Disorders • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Meningococcal Infections • Multiple Myeloma • Myelodysplastic Syndrome • Neutropenia • Oncology • Septic Shock • Small Lymphocytic Lymphoma • IGH

COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) AND ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION FOR PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (EHA 2025) - P1, P3 | "The phase 3 SYMPATICO study showed that combination therapy with venetoclax, a BCL2 inhibitor (BCL2i), and ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), had efficacy in patients (pts) with relapsed/refractory (R/R) MCL; however, treatment intolerance may impact its use. Sonrotoclax + zanu combination therapy was well tolerated and demonstrated encouraging antitumor activity, with a CR rate of 62.2%, and responses in pts previously treated with a BTKi. A registrational phase 3 study (NCT06742996) further assessing this combination with sonrotoclax 320mg is recruiting."

Clinical • Atrial Fibrillation • Cardiovascular • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Myelodysplastic Syndrome • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock

UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS WITH T(11; 14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN ALL-ORAL TREATMENT (EHA 2025) - P1/2 | "Sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no drug accumulation. The all-oral combination of sonrotoclax + dex continued to show a tolerable safety profile, with low rates of infection and hematologic toxicity, and promising efficacy, with an ORR of 81% in the 640-mg cohort, in this t(11; 14)-positive R/R MM population. The study is ongoing; additional tx combinations with sonrotoclax are being investigated."

Clinical • CNS Disorders • Fatigue • Hematological Malignancies • Infectious Disease • Insomnia • Multiple Myeloma • Oncology • Pancreatic Cancer • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • Sleep Disorder • Solid Tumor

UPDATED SAFETY AND EFFICACY RESULTS OF A PHASE 1 STUDY OF THE NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) FOR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (EHA 2025) - P1 | "Venetoclax, the first-generation BCL2 inhibitor, has antitumor activity in patients with WM, but it is not approved for the treatment of this disease. Sonrotoclax monotherapy has encouraging antitumor activity, with ORRs of 78.3% across dose levels and 100% at sonrotoclax RP2D (320 mg) in heavily pre-treated patients with R/R WM and has demonstrated a tolerable safety profile across all dose levels tested. Based on the findings of this study, further evaluation of sonrotoclax monotherapy in patients with R/R WM is ongoing in a potentially pivotal phase 2 study."

Clinical • P1 data • Anemia • Cardiovascular • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Neutropenia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Waldenstrom Macroglobulinemia

PRIMARY ANALYSIS RESULTS OF NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (EHA 2025) - P1 | "Background: The first-generation B-cell lymphoma 2 (BCL2) inhibitor venetoclax is an effective treatment for patients with B-cell malignancies; however, its clinical use can be limited by toxicity. Sonrotoclax monotherapy was well tolerated in patients with R/R NHL and CLL/SLL at doses up to 640 mg once daily, with no cases of TLS reported and low rates of discontinuation due to TEAEs. Patients with R/R CLL/SLL had an ORR of 72% with deep responses (best blood uMRD4 rate of 41.4%, and 31% achieved a CR)."

Clinical • Monotherapy • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Leukemia • Lymphoma • Marginal Zone Lymphoma • Oncology • Small Lymphocytic Lymphoma

SONROTOCLAX MONOTHERAPY FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLL: DATA FROM AN ONGOING PHASE 1/1B STUDY (BGB-11417-101) (EHA 2025) - P1 | "Sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, is a more selective and potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no drug accumulation. Sonrotoclax monotherapy had a tolerable safety profile across all doses tested and had encouraging antitumor activity in patients with R/R CLL/SLL, most of whom received prior BTK inhibitors. No clinical TLS events were observed, indicating that TLS can be prevented with current measures. Based on this data, sonrotoclax is being tested with different regimens in pivotal studies."

Clinical • IO biomarker • Monotherapy • P1 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Cough • Hematological Disorders • Infectious Disease • Lymphoma • Neutropenia • Oncology • Respiratory Diseases • Thrombocytopenia • IGH

THE SAFETY AND EFFICACY OF SONROTOCLAX COMBINED WITH AZACITIDINE (AZA) AND HAG IN PATIENTS (PTS) WITH REFRACTORY/ RELAPSED (R/R) ACUTE MYELOID LEUKEMIA (AML): A PHASE II STUDY (EHA 2025) - "Venetoclax (VEN) combined with hypomethylating agents (HMA) have been the standard treatment for newly diagnosed unfit AML pts...VEN plus HMA and CAG (aclarubicin, cytarabine, G-CSF) for R/R AML achieved a CR/CRi rate of 85%, allo-HSCT rate of 55% and 1-year OS rate of 60% (Liu Y et al, 2023)...HAG (homoharringtonine, cytarabine, G-CSF), a priming regimen, is an effective and safe treatment commonly used in Asia for R/R AML...Maintenance includes a 28-day cycle of sonrotoclax combined with AZA until intolerable toxicity, 10 months, recurrence, death, withdraw informed consent or study termination determined by investigator.The primary endpoint is 1-year OS rate assessed by investigator. The secondary endpoints include OS, CRc rate at the end of induction, MRD negative rate (MRD <0.1% by MFC), DOR, EFS, RFS and safety."

Clinical • P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • ENG

UPDATED SAFETY & ANTILEUKEMIC ACTIVITY DATA OF SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN TREATMENT-NAIVE PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR INTENSIVE CHEMOTHERAPY (EHA 2025) - P1/2 | "Background: B-cell lymphoma 2 (BCL2) inhibitor venetoclax + azacitidine (AZA) has improved outcomes in treatment-naive patients (pts) with newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy (TN unfit AML), with median overall survival of 14.7 mo and complete remission in 36.7% of pts. In BGB-11417-103, a phase 1b/2 trial, sonrotoclax + AZA was more tolerable in cycles with shorter tx duration and had promising antileukemic activity, with the potential for deeper responses at higher exposures. TEAE frequency and severity were similar across all cohorts. Further evaluation in pts with TN unfit AML is ongoing."

Clinical • Acute Myelogenous Leukemia • Anemia • B Cell Lymphoma • Febrile Neutropenia • Infectious Disease • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Neutropenia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

UPDATED SAFETY AND ANTILEUKEMIC ACTIVITY DATA FOR SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (EHA 2025) - P1/2 | "Background: Treatment with venetoclax, a B‑cell lymphoma 2 (BCL2) inhibitor, has improved outcomes in patients with newly diagnosed acute myeloid leukemia (AML), but it is not approved for relapsed/refractory (R/R) AML. In BGB‑11417‑103, a phase 1b/2 trial, sonrotoclax + azacitidine was well tolerated and demonstrated promising antileukemic activity in patients with R/R AML. Further evaluation in patients with R/R AML is ongoing."

Clinical • Acute Myelogenous Leukemia • Anemia • B Cell Lymphoma • Febrile Neutropenia • Infectious Disease • Lymphoma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Neutropenia • Septic Shock • Thrombocytopenia

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov) - P3 | N=630 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

Diagnosis and Management of Waldenstrom's Macroglobulinemia. (PubMed, Hematol Oncol) - "The cBTK-i zanubrutinib shows greater response activity and/or improved progression-free survival in WM patients with wild-type MYD88, mutated CXCR4, or altered TP53. New or emerging options for patients progressing on c-BTKi include pirtobrutinib, BGB-16673, venetoclax, and sonrotoclax. Combinations of BTK inhibitors with chemoimmunotherapy and BCL2 antagonists have advanced. Algorithms for patients with treatment-naïve and previously treated WM based on genomics, disease characteristics, and co-morbidities are discussed."

IO biomarker • Journal • Review • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia • BCL2 • CXCR4 • MYD88 • TP53

Sonrotoclax + BRUKINSA Demonstrates Deep Responses in CLL and MCL (Businesswire) - P1 | N=437 | BGB-11417-101 (NCT04277637) | Sponsor: BeiGene | "Updated results from Phase 1 studies evaluating sonrotoclax in combination with BRUKINSA in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and with R/R mantle cell lymphoma (MCL) demonstrated consistent, deep responses and a manageable safety profile...R/R CLL/SLL (Oral Presentation S159):Overall response rate (ORR): 96%; complete response (CR): 52% across all dose levels; R/R MCL (Oral Presentation S234):ORR: 79%; CR rate: 66%, with 84% of responders in ongoing response at data cutoff"

P1 data • Chronic Lymphocytic Leukemia • Mantle Cell Lymphoma